A5005726073- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Cancer survivorship and care
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Gene expression and cancer classification
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Health Systems, Economic Evaluations, Quality of Life
- DNA Repair Mechanisms
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- PARP inhibition in cancer therapy
Duke University
2015-2025
Duke Medical Center
2013-2023
Duke Cancer Institute
2013-2023
Cancer Institute (WIA)
2015-2023
Veracyte (United States)
2023
Washington University in St. Louis
2023
Duke University Hospital
2008-2022
Oregon Health and Science University Hospital
2022
University Medical Center
2021
Clinical Research Institute
2016
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients metastatic breast cancer previously treated an anthracycline taxane.Patients were randomly assigned receive (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone combination bevacizumab (15 mg/kg) 1. The primary end point was progression-free survival (PFS), as determined by independent review...
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five (RUNX1, CBFB, MYH9, MLL3 SF3B1) previously linked to haematopoietic disorders. Mutant MAP3K1 was associated luminal A status, low-grade histology...
Purpose Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined. Patients Methods Clinically annotated, microarray data from 784 early-stage breast cancers were identified, prospectively defined, age-specific cohorts (young: ≤ 45 years, n = 200; older: ≥ 65 211) compared by prognosis, variables, mRNA expression values, single-gene analysis, gene set...
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these have been ineligible the pivotal trials adjuvant trastuzumab.We performed an uncontrolled, single-group, multicenter, investigator-initiated study paclitaxel and trastuzumab in 406 tumors measuring up to 3 cm greatest dimension. Patients received weekly 12 weeks, followed by 9 months monotherapy. The primary end point...
During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial (MET) as part of a broad invasion metastasis program. We previously observed MET events among lung metastases in preclinical model prostate adenocarcinoma that suggested relationship between epithelial plasticity metastatic spread. thus sought to translate these findings into clinical evidence by examining the existence EMT circulating tumor (CTC) from patients with...
This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.Heavily pretreated metastatic cancers were randomly assigned to one five dose cohorts administered once daily. Pharmacokinetic samples obtained on days 1 20. Clinical response was every 8 weeks.Sixty-seven tumors treated lapatinib. The most frequently...
All cancers develop as a result of mutations in certain genes, such those involved the regulation cell growth and/or DNA repair, 1,2 but not all these are inherited from parent.For example, sporadic can occur somatic/ tumor cells only, and de novo for first time germ (i.e., egg or sperm) fertilized itself during early embryogen-
PURPOSE: Weight gain is a common problem among breast cancer patients who receive adjuvant chemotherapy (CT). We undertook study to determine the causes of this energy imbalance. PATIENTS AND METHODS: Factors related balance were assessed at baseline (within 3 weeks diagnosis) and throughout 1 year postdiagnosis 53 premenopausal women with operable carcinoma. Thirty-six received CT 17 only localized treatment (LT). Measures included body composition (dual x-ray absorptiometry), resting...
Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed select agents III investigations.Three hundred seventy-seven postmenopausal women with clinical stage ER-positive (Allred score 6-8) cancer randomly assigned receive exemestane, letrozole, or anastrozole. The primary end point was response....
Epidermal growth factor receptor (EGFR) is a targetable frequently overexpressed in basal-like breast cancer, which comprises most triple-negative cancers (TNBCs), the only subtype without established targeted therapy.In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m(2) load then 250 per week intravenously [IV]) alone, carboplatin (area under curve of 2, once IV) added after progression or as concomitant therapy from beginning....
These NCCN Guidelines Insights highlight the important updates/changes to surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in 1.2017 version of Breast Cancer. This report summarizes these updates discusses rationale behind them. Updates on new drug approvals, not available at press time, can be found most recent guidelines NCCN.org.
Purpose: To prospectively determine cancer yield, callback and biopsy rates, positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, ultrasonography (US) in women at high risk for breast cancer. Materials Methods: The study was approved by the institutional review board HIPAA compliant, informed consent obtained. We conducted a prospective pilot screening MR, US asymptomatic 25 years age or older who were genetically risk, defined as BRCA1/BRCA2 carriers with least...
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Olaparib Expanded, an investigator-initiated, phase II study, assessed olaparib response patients with MBC somatic (s)BRCA1/2 mutations or g/s homologous recombination (HR)-related genes other than BRCA1/2.Eligible had measurable disease and non-BRCA1/2 HR-related...
This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies.Heavily pretreated metastatic cancers overexpressing ErbB2 expressing were randomly assigned one five dose cohorts (GW572016) administered orally once daily continuously. The growth and survival assessed biopsies obtained before after 21 days therapy. Clinical response determined at 8 weeks.Sequential from...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations genetic testing counseling risk assessment management hereditary cancer syndromes. focus on syndromes associated with an increased of breast and/or ovarian are intended to assist clinical shared decision-making. These Insights summarize major discussion points the 2015 panel meeting. Major topics this year included multigene testing, less common mutations, salpingectomy reduction. also...
The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. primary analysis the demonstrated a 3-year disease-free survival (DFS) 98.7%. In this planned secondary analysis, we report longer-term outcomes exploratory results characterize biology HER2-positive tumors genetic factors that may predispose paclitaxel-induced peripheral neuropathy (TIPN).In phase II study, cancer 3 cm...
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses rationale behind them.
Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined vinorelbine, assess cardiac surveillance algorithms tumor markers as prognostic tools.Patients HER2-positive (immunohistochemistry [IHC] 3+-positive or fluorescence in situ hybridization [FISH]-positive) metastatic cancer received first-line chemotherapy...
The optimal trastuzumab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that designed to compare these regimens.Eligible patients had received no prior advanced disease. Patients were 1:1 receive either with weekly therapy (paclitaxel docetaxel at the investigator's choice). Originally planned 250 patients, closed because of poor accrual 81...
These NCCN Guidelines Insights highlight the important updates specific to management of HER2-positive metastatic breast cancer in 2013 version Clinical Practice Oncology for Breast Cancer. include new first-line and subsequent therapy options patients with cancer.
During the past few years, several genetic aberrations that may contribute to increased risks for development of breast and/or ovarian cancers have been identified. The NCCN Guidelines Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on assessment mutations in BRCA1/BRCA2, TP53, PTEN, recommend approaches testing/counseling management strategies individuals with these mutations. This portion includes recommendations regarding diagnostic criteria patients Cowden...
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This portion NCCN Guidelines discusses recommendations specific locoregional clinical stage I, II, IIIA (T3N1M0) tumors.